Clinical Trials · NCT00928434
A Study of Degarelix in Patients With Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 409
- Start date
- May 2009
- Locations
- 59 sites, United States
- Primary endpoint
- Percentage of Patients With Serum PSA Levels ≤4.0 ng/mL